Valentina Vengeliene1,2, Nazzareno Cannella3, Tatiane Takahashi3, Rainer Spanagel3. 1. Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. valentina.vengeliene@zi-mannheim.de. 2. Institute of Psychopharmacology, Central Institute of Mental Health, J5, 68159, Mannheim, Germany. valentina.vengeliene@zi-mannheim.de. 3. Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Abstract
RATIONALE: The glutamatergic system plays a key role in the maintenance of drug use and development of drug-related conditioned behaviours. In particular, hyper-glutamatergic activity and N-methyl-D-aspartate receptor (NMDAR) activation may drive drug craving and relapse. Inhibition of kynurenine-3-monooxygenase (KMO) shifts the metabolic kynurenine pathway towards production of kynurenic acid, which leads to a reduction of glutamatergic/NMDAR activity via different mechanisms. OBJECTIVES: In this study, we investigated whether drug-seeking and relapse behaviour could be modified by the metabolic shift of endogenous kynurenine pathway. METHODS: An inhibitor of kynurenine-3-monooxygenase (KMO) Ro61-8048 (4 and 40 mg/kg) and its prodrug JM6 (100 and 200 mg/kg) were tested in two behavioural rat models for drug seeking and relapse-the alcohol deprivation effect (ADE) model in long-term alcohol-drinking rats and the model of cue-induced reinstatement of alcohol- and cocaine-seeking behaviour. RESULTS: Our results show that relapse-like alcohol drinking during the ADE was abolished by repeated intraperitoneal administration of Ro61-8048 and significantly reduced by its oral prodrug JM6. Cue-induced reinstatement of both alcohol- and cocaine-seeking behaviour was also abolished by administration of Ro61-8048. CONCLUSIONS: Pharmacological enhancement of endogenous kynurenic acid levels provides a novel treatment strategy to interfere with glutamatergic/NMDAR activity as well as with craving and relapse in alcohol-dependent patients and drug addicts.
RATIONALE: The glutamatergic system plays a key role in the maintenance of drug use and development of drug-related conditioned behaviours. In particular, hyper-glutamatergic activity and N-methyl-D-aspartate receptor (NMDAR) activation may drive drug craving and relapse. Inhibition of kynurenine-3-monooxygenase (KMO) shifts the metabolic kynurenine pathway towards production of kynurenic acid, which leads to a reduction of glutamatergic/NMDAR activity via different mechanisms. OBJECTIVES: In this study, we investigated whether drug-seeking and relapse behaviour could be modified by the metabolic shift of endogenous kynurenine pathway. METHODS: An inhibitor of kynurenine-3-monooxygenase (KMO) Ro61-8048 (4 and 40 mg/kg) and its prodrug JM6 (100 and 200 mg/kg) were tested in two behavioural rat models for drug seeking and relapse-the alcohol deprivation effect (ADE) model in long-term alcohol-drinking rats and the model of cue-induced reinstatement of alcohol- and cocaine-seeking behaviour. RESULTS: Our results show that relapse-like alcohol drinking during the ADE was abolished by repeated intraperitoneal administration of Ro61-8048 and significantly reduced by its oral prodrug JM6. Cue-induced reinstatement of both alcohol- and cocaine-seeking behaviour was also abolished by administration of Ro61-8048. CONCLUSIONS: Pharmacological enhancement of endogenous kynurenic acid levels provides a novel treatment strategy to interfere with glutamatergic/NMDAR activity as well as with craving and relapse in alcohol-dependent patients and drug addicts.
Authors: Justin T Gass; Courtney M Sinclair; Richard M Cleva; John J Widholm; M Foster Olive Journal: Addict Biol Date: 2010-11-04 Impact factor: 4.280
Authors: Daniel Zwilling; Shao-Yi Huang; Korrapati V Sathyasaikumar; Francesca M Notarangelo; Paolo Guidetti; Hui-Qiu Wu; Jason Lee; Jennifer Truong; Yaisa Andrews-Zwilling; Eric W Hsieh; Jamie Y Louie; Tiffany Wu; Kimberly Scearce-Levie; Christina Patrick; Anthony Adame; Flaviano Giorgini; Saliha Moussaoui; Grit Laue; Arash Rassoulpour; Gunnar Flik; Yadong Huang; Joseph M Muchowski; Eliezer Masliah; Robert Schwarcz; Paul J Muchowski Journal: Cell Date: 2011-06-10 Impact factor: 41.582
Authors: Rainer Spanagel; Daniel Durstewitz; Anita Hansson; Andreas Heinz; Falk Kiefer; Georg Köhr; Franziska Matthäus; Markus M Nöthen; Hamid R Noori; Klaus Obermayer; Marcella Rietschel; Patrick Schloss; Henrike Scholz; Gunter Schumann; Michael Smolka; Wolfgang Sommer; Valentina Vengeliene; Henrik Walter; Wolfgang Wurst; Uli S Zimmermann; Sven Stringer; Yannick Smits; Eske M Derks Journal: Addict Biol Date: 2013-11 Impact factor: 4.280
Authors: Pablo Giménez-Gómez; Mercedes Pérez-Hernández; Esther O'Shea; Javier R Caso; David Martín-Hernandez; Luis Alou Cervera; María Luisa Gómez-Lus Centelles; María Dolores Gutiérrez-Lopez; Maria Isabel Colado Journal: FASEB J Date: 2019-09-11 Impact factor: 5.191
Authors: Ryan W Logan; Puja K Parekh; Gabrielle N Kaplan; Darius D Becker-Krail; Wilbur P Williams; Shintaro Yamaguchi; Jun Yoshino; Micah A Shelton; Xiyu Zhu; Hui Zhang; Spencer Waplinger; Ethan Fitzgerald; Jeffrey Oliver-Smith; Poornima Sundarvelu; John F Enwright; Yanhua H Huang; Colleen A McClung Journal: Mol Psychiatry Date: 2018-05-04 Impact factor: 15.992